Published in Hum Vaccin Immunother on November 15, 2016
Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37
Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release (2006) 3.85
Dissolving polymer microneedle patches for influenza vaccination. Nat Med (2010) 3.24
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol (2008) 2.88
Dissolving microneedles for transdermal drug delivery. Biomaterials (2008) 2.47
Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat Med (2002) 2.42
Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol (2011) 2.25
Cutaneous dendritic cells. Semin Immunol (2005) 1.94
Design, optimization and characterisation of polymeric microneedle arrays prepared by a novel laser-based micromoulding technique. Pharm Res (2010) 1.76
Microneedle technologies for (trans)dermal drug and vaccine delivery. J Control Release (2012) 1.49
Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines (2012) 1.44
DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine (2009) 1.37
Migration of langerhans cells and dermal dendritic cells in skin organ cultures: augmentation by TNF-alpha and IL-1beta. J Leukoc Biol (1999) 1.26
Microfabricated silicon microneedles for nonviral cutaneous gene delivery. Br J Dermatol (2004) 1.25
Fabrication of dissolving polymer microneedles for controlled drug encapsulation and delivery: Bubble and pedestal microneedle designs. J Pharm Sci (2010) 1.13
Cutaneous vaccination using microneedles coated with hepatitis C DNA vaccine. Gene Ther (2010) 1.11
A proposed model membrane and test method for microneedle insertion studies. Int J Pharm (2014) 1.05
Langerin negative dendritic cells promote potent CD8+ T-cell priming by skin delivery of live adenovirus vaccine microneedle arrays. Proc Natl Acad Sci U S A (2013) 1.05
Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. Vaccine (2001) 1.03
Delivery and expression of pDNA embedded in collagen matrices. J Control Release (2004) 1.03
Comparison of body distribution of poly(vinyl alcohol) with other water-soluble polymers after intravenous administration. J Pharm Pharmacol (1995) 0.98
Design and physicochemical characterisation of novel dissolving polymeric microneedle arrays for transdermal delivery of high dose, low molecular weight drugs. J Control Release (2014) 0.94
DNA vaccines: roles against diseases. Germs (2013) 0.92
Dissolvable microneedle patches for the delivery of cell-culture-derived influenza vaccine antigens. J Pharm Sci (2011) 0.92
Cell death in mammalian cell culture: molecular mechanisms and cell line engineering strategies. Cytotechnology (2010) 0.91
Advances with the use of bio-inspired vectors towards creation of artificial viruses. Expert Opin Drug Deliv (2010) 0.89
Microneedle delivery of plasmid DNA to living human skin: Formulation coating, skin insertion and gene expression. J Control Release (2012) 0.89
Development and characterization of self-assembling nanoparticles using a bio-inspired amphipathic peptide for gene delivery. J Control Release (2014) 0.89
Visualization of plasmid delivery to keratinocytes in mouse and human epidermis. Sci Rep (2011) 0.89
Increased immunogenicity of avian influenza DNA vaccine delivered to the skin using a microneedle patch. Eur J Pharm Biopharm (2012) 0.88
Clinical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch. Biomaterials (2015) 0.87
Langerin+ dermal dendritic cells are critical for CD8+ T cell activation and IgH γ-1 class switching in response to gene gun vaccines. J Immunol (2010) 0.87
Pharmacokinetics and biodisposition of poly(vinyl alcohol) in rats and mice. Drug Metab Pharmacokinet (2005) 0.86
Protective interactive noncondensing (PINC) polymers for enhanced plasmid distribution and expression in rat skeletal muscle. J Control Release (1998) 0.86
Production of dissolvable microneedles using an atomised spray process: effect of microneedle composition on skin penetration. Eur J Pharm Biopharm (2013) 0.85
Monitoring the penetration process of single microneedles with varying tip diameters. J Mech Behav Biomed Mater (2014) 0.84
A novel scalable manufacturing process for the production of hydrogel-forming microneedle arrays. Int J Pharm (2015) 0.83
Basic histological structure and functions of facial skin. Clin Dermatol (2013) 0.82
Excretion and distribution studies in rats with two forms of 14carbon-labelled polyvinylpyrrolidone with a relatively low mean molecular weight after intravenous administration. Arzneimittelforschung (1977) 0.81
Localized reactions to injected therapeutic materials. Part 2. Surgical agents. J Cutan Pathol (1995) 0.81
Retention and storage sites of radioactive polyvinylpyrrolidone. J Nucl Med (1968) 0.80
DNA-based vaccination against hepatitis B virus using dissolving microneedle arrays adjuvanted by cationic liposomes and CpG ODN. Drug Deliv (2015) 0.79
Transcending epithelial and intracellular biological barriers; a prototype DNA delivery device. J Control Release (2016) 0.79
Microneedles: an innovative platform for gene delivery. Drug Deliv Transl Res (2015) 0.79
Development of a method to quantify the DNA content in cationic peptide-DNA nanoparticles. J Pharm Biomed Anal (2014) 0.78
DNA vaccination for prostate cancer: key concepts and considerations. Cancer Nanotechnol (2015) 0.78
Sustained release of complexed and naked DNA from polymer films. J Biomed Mater Res B Appl Biomater (2008) 0.77
Polyvinyl pyrrolidone promotes DNA cleavage by a ROS-independent and depurination mechanism. Environ Sci Technol (2013) 0.76